Fig. 5

Spinal changes of STING expression after neuraxial morphine, dry skin and contact dermatitis. STING agonist DMXAA (i.p., 20 mg/kg) was administered 60 min prior to morphine (i.t., 0.3 nmol) exposure. A and B Immunostaining showed the fluorescence intensity of STING (red) in the spinal dorsal horn at 30 min after morphine injection. Scale bar, 100 μm. C and D Western blot showed that DMXAA treatment affects spinal STING expression at 30 min after morphine injection. E and F Western blot showed that two injections of DMXAA (i.p., 20 mg/kg) daily from day 1 to 2 after AEW exposure affect spinal STING expression on day 3 after AEW intervention. G and H Western blot showed that two injections of DMXAA (i.p., 20 mg/kg) daily from day 3 to 4 after DCP exposure affect spinal STING expression on day 5 after DCP intervention. n = 4–6 mice/group. Data are expressed as mean ± SD and analyzed by one-way ANOVA with Bonferroni post hoc test